www.uhasselt.be
DSpace

Document Server@UHasselt >
Research >
Research publications >

Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/2882

Title: Response criteria for clinical trials on osteoarthritis of the knee and hip - A report of The Osteoarthritis Research Society International Standing Committee for Clinical Trials Response Criteria Initiative
Authors: Dougados, M
LeClaire, P
VAN DER HEIJDE, Desiree
Bloch, DA
Bellamy, N.
Altman, R.D.
Issue Date: 2000
Publisher: W B SAUNDERS CO LTD
Citation: OSTEOARTHRITIS AND CARTILAGE, 8(6). p. 395-403
Abstract: Background: The domains of pain, function and patient's global assessment are identified as core variables and frequently measured in clinical trials of patients with osteoarthritis (OA) of the hip and knee. Objective: To develop response criteria for OA of hip and knee based on the domains of pain, function and patient's global assessment. Methods: A methodology was developed by an interaction of the Osteoarthritis Research Society International Standing Committee on Clinical Trials, biostatisticians, pharmaceutical company representatives and health agency representatives. Data from previously conducted placebo-controlled clinical trials were normalized and collated. Data were subset by location of OA (knee, hip), active agent used in the clinical trial (non-steroidal anti-inflammatory drug, other agent) and route of administration (oral, intra-articular). Statistical analysis identified response criteria which best discriminate active agent from placebo. Results: Based on the analysis of data from 14 studies (totaling 1886 patients) and consensus opinion, the optimal responder criteria set differed for location of OA, active agent to be used, and route of administration. Because of nearly identical statistical results, two sets of responder criteria are proposed: (1) 'high' pain response or, alternatively, a 'moderate' response for at least two of three domains: pain, function and patient's global assessment; (2) 'high' response for either pain or function or, alternatively, a 'moderate' response for at least two of three domains: pain, function and patient's global assessment. The sensitivity (i.e., the percentage of responders in the active group) ranged from 52 to 96% and the specificity (i.e., the percentage of nonresponders in the control group) from 47 to 73%. Conclusion: Based on data from clinical trials, two sets of responder criteria have been developed that can categorize an individual's responses to treatment in a clinical trial. These responder criteria require validation in additional datasets. (C) 2000 OsteoArthritis Research Society International.
Notes: Vet Affairs Med Ctr, Miami, FL 33125 USA. Hop Cochin, Inst Rhumatol, F-75014 Paris, France. Univ Hosp Maastricht, Dept Rheumat Dis, NL-6202 AZ Maastricht, Netherlands. Limburgs Univ Ctr, Diepenbeek, Belgium. Stanford Univ, Dept Hlth Res & Policy, Stanford, CA 94305 USA. Univ Queensland, Royal Brisbane Hosp, Ctr Natl Res Disabil & Rehab Med, Brisbane, Qld 4029, Australia.Altman, RD, Vet Affairs Med Ctr, NH207G,1201 NW 16th St, Miami, FL 33125 USA.
URI: http://hdl.handle.net/1942/2882
ISI #: 000165771000001
ISSN: 1063-4584
Category: A1
Type: Journal Contribution
Validation: ecoom, 2001
Appears in Collections: Research publications

Files in This Item:

There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.